Cargando…

Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis

BACKGROUND: Heart failure (HF) is a major cause of recurrent hospitalization and death worldwide. Sodium-glucose cotransporter-2 inhibitors including dapagliflozin are anti-diabetic drugs with promising cardiovascular (CV) effects. We performed systematic review and meta-analysis of randomized contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Ahmed E., Mazroua, Muhammad Sabry, ElSaban, Mariam, Najam, Nadia, Kothari, Aditi S., Mansoor, Taha, Amal, Tanya, Lee, Joanna, Kashyap, Rahul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ubiquity Press 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453961/ https://www.ncbi.nlm.nih.gov/pubmed/37636033 http://dx.doi.org/10.5334/gh.1258

Ejemplares similares

A historical delve into neurotrauma-focused critical care
por: ElSaban, Mariam, et al.
Publicado: (2023)

Editorial: Global excellence in intensive care medicine and anesthesiology: North America
por: ElSaban, Mariam, et al.
Publicado: (2022)

Current Status of Dapagliflozin in Congestive Heart Failure
por: Palandurkar, Gopal, et al.
Publicado: (2022)

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
por: Yeoh, Su Ern, et al.
Publicado: (2023)

The effect of Dapagliflozin on renal functions in hospitalized patients with Acute Heart Failure
por: Gilani, Syedah Fauzia Fatima, et al.
Publicado: (2023)

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
por: Gupta, Manasvi, et al.
Publicado: (2021)

Relevance of Anthropometric Measurements in a Multiethnic Obesity Cohort: Observational Study
por: Bhatti, Rahila, et al.
Publicado: (2021)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
por: Williams, David M., et al.
Publicado: (2020)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

Dapagliflozin for heart failure according to body mass index: the DELIVER trial( )
por: Adamson, Carly, et al.
Publicado: (2022)

Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure
por: Nazer, Rakan, et al.
Publicado: (2022)

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
por: Serenelli, Matteo, et al.
Publicado: (2020)

An Inquiry-Based Distance Learning Tool for Medical Students Under Lockdown (“COVID-19 Rounds”): Cross-Sectional Study
por: Akhras, Aya, et al.
Publicado: (2023)

Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis
por: Cai, Ru-ping, et al.
Publicado: (2021)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review
por: Wu, Meiyu, et al.
Publicado: (2022)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea
por: Jaffuel, Dany, et al.
Publicado: (2023)

Dapagliflozin-affected endothelial dysfunction and altered gut microbiota in mice with heart failure
por: Bao, Nandi, et al.
Publicado: (2023)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
por: Mendoza, Victor L., et al.
Publicado: (2021)

Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients
por: Wang, Chuanqiang, et al.
Publicado: (2022)

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
por: Adamson, Carly, et al.
Publicado: (2021)

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
por: Vardeny, Orly, et al.
Publicado: (2022)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
por: Nakagaito, Masaki, et al.
Publicado: (2019)

Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
por: Singh, Jagdeep S.S., et al.
Publicado: (2020)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients
por: Reis, João, et al.
Publicado: (2022)

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure
por: Xanthopoulos, Andrew, et al.
Publicado: (2023)

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
por: Escobar, Carlos, et al.
Publicado: (2023)

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Chatur, Safia, et al.
Publicado: (2023)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction
por: Tang, Yi, et al.
Publicado: (2023)

Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction
por: Ibrahim, Ayman, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t620a1e469csn22tsv051cpd4j